Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma

Questions: Discounts, Updates etc.

Price (Single): $3,800.00

Price (Departmental):

Price (Company):

Publication Date: 2007-03-13

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

SCLC accounts for one-fifth of all lung tumor types. More than 80,000 new cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.

Scope

  • Evaluate opportunities and risks in the SCLC and mesothelioma markets by analyzing the clinical and commercial attractiveness of key drugs
  • Assess key success factors that drive the SCLC and mesothelioma markets to estimate the potential of existing and pipeline drugs for the diseases
  • Understand current and future competitive dynamics of SCLC and mesothelioma to determine the future size and scope of the markets

    •  

  • Overview of small cell lung cancer (SCLC) and mesothelioma, including epidemiology, staging, prognosis and unmet needs
  • Review of current treatment modalities and physician opinion of existing and future treatment strategies
  • Evaluation of key drugs currently used in the treatment of SCLC and mesothelioma
  • Assessment of late-phase drugs in development for SCLC and mesothelioma including key opinion leaders' view on their potential

    •  

    Report Highlights
    Despite decreasing incidence, unmet needs in SCLC remain high due to poor prognosis and lack of effective treatment. R&D interest in the disease is low; however, this represents an opportunity for developing companies in the SCLC market.

    Alimta is approved for other lung cancer indications including NSCLC and mesothelioma. It is in a Phase III trial in SCLC and Datamonitor believes that, although unlikely to show significant efficacy advantage over current standard, Alimta may potentially demonstrate toxicity advantages, in which case, it may usurp etoposide as standard therapy.

    Incidence of malignant mesothelioma may have peaked in the US but is set to increase over the next two decades in Europe and Japan due to the later uptake of asbestos in these markets. Nevertheless, overall incidence of mesothelioma remains low; as is the R&D interest in the disease.

    Reasons to Purchase

    Table of Contents

    Other users found this report page using the following search terms: small cell lung cancer lung cancer sclc mesothelioma survival incidence lung cancer vorinostat development results rates malignant

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.